Abstract
PURPOSE OF REVIEW: The goal of this review is to update ophthalmologists and orbital and adnexal specialists with the emerging role of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and adnexal non-Hodgkin's lymphoma and other lymphoproliferative disorders of the orbit. RECENT FINDINGS: Rituximab as monotherapy for indolent lymphoma of the orbit and conjunctiva may be associated with good initial response, but the risk of distant relapse is about 50%. Rituximab may be used in combination with conventional chemotherapy, and such combination therapy may be associated with a higher durable response rate and improved progression-free survival compared with chemotherapy alone. Radioimmunotherapy using targeted monoclonal antibodies with radioactive conjugates is also associated with a more durable response rate than monotherapy with rituximab alone and may be an alternative for treatment of ocular adnexal lymphoma. Radioimmunoconjugates are associated with transient pancytopenia during the first 3 months after treatment. Rituximab monotherapy may be considered as an alternative to systemic steroids for treatment of orbital benign lymphoid hyperplasia. SUMMARY: Targeted monoclonal antibody therapy is an intriguing new modality for treatment of orbital, eyelid, or conjunctival lymphoma and can be used in combination with radioimmunotherapy or standard chemotherapy for a more durable response.
Original language | English (US) |
---|---|
Pages (from-to) | 414-421 |
Number of pages | 8 |
Journal | Current opinion in ophthalmology |
Volume | 19 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2008 |
Keywords
- Anti-CD20 therapy
- Benign lymphoid hyperplasia
- Conjunctival lymphoma
- Monoclonal antibody therapy
- Orbital lymphoma
- Radioimmunotherapy
- Targeted therapy
ASJC Scopus subject areas
- Ophthalmology